Patient fails organ-function thresholds for CAR-T cell therapy: any of LVEF <40%, CrCl <3...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-CAR-T-INELIGIBLE-ORGAN |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-TRANSCEND-NHL-001-ABRAMSON-2020 SRC-ZUMA-1-NEELAPU-2017 |
Red Flag Origin
| Definition | Patient fails organ-function thresholds for CAR-T cell therapy: any of LVEF <40%, CrCl <30 mL/min, bilirubin >2× ULN (non-Gilbert / non-disease- related), AST/ALT >5× ULN, severe pulmonary disease (DLCO <40% or O2 requirement), or uncontrolled active infection. Triggers exclusion from CAR-T pathways and pivot to bispecific antibodies, ADC, or salvage chemotherapy. |
|---|---|
| Clinical direction | hold |
| Category | organ-dysfunction |
Trigger Logic
{
"any_of": [
{
"comparator": "<",
"finding": "lvef_percent",
"threshold": 40
},
{
"comparator": "<",
"finding": "creatinine_clearance_ml_min",
"threshold": 30
},
{
"comparator": ">",
"finding": "bilirubin_ratio_to_uln",
"threshold": 2
},
{
"comparator": ">",
"finding": "ast_alt_ratio_to_uln",
"threshold": 5
},
{
"finding": "active_uncontrolled_infection",
"value": true
}
],
"type": "composite_score"
}
Notes
Pivotal trial exclusions; real-world data (CIBMTR, French DESCAR-T) suggest some flexibility but at increased CRS/ICANS-mortality cost. Alternatives by disease: DLBCL/HGBL — bispecifics (epcoritamab, glofitamab), polatuzumab + bendamustine + rituximab (POLARIX salvage setting), tafasitamab + lenalidomide (L-MIND); MCL — pirtobrutinib, bendamustine-based regimens; multiple myeloma — talquetamab, teclistamab, elranatamab, selinexor combinations, belantamab. Direction `hold` for CAR-T pathway only; other systemic therapy remains feasible with attenuation per RF-ORGAN-* siblings.
Used By
Algorithms
ALGO-MCL-2L- ALGO-MCL-2L
Red flag
RF-CAR-T-INELIGIBLE-AGE-COMORBID- Composite age + comorbidity exclusion from CAR-T: age ≥75 with Charlson Comorbidity Index...RF-DLBCL-CART-INELIGIBLE-POST-2L- Relapsed/refractory DLBCL post ≥2 prior systemic therapies, NOT a candidate for anti-CD19...RF-DLBCL-CD20-POS-EPCORITAMAB-CANDIDATE- Relapsed/refractory DLBCL with confirmed CD20 expression on malignant B-cells, post ≥2 pr...RF-DLBCL-CD20-POS-GLOFITAMAB-CANDIDATE- Relapsed/refractory DLBCL with confirmed CD20 expression on malignant B-cells, post ≥2 pr...